These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31790621)

  • 1. The relationship between
    Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
    J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
    Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
    Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.
    Ghazi Jumaa M
    Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
    Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
    Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
    Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
    Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
    Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
    Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
    Bastit V; Bon-Mardion N; Picquenot JM; Rainville V; Moldovan C; François A; Loeb A; Thureau S; Manu D; Jardin F; Marie JP; Di Fiore F; Clatot F
    Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):541-550. PubMed ID: 30523411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.
    Grechukhina O; Petracco R; Popkhadze S; Massasa E; Paranjape T; Chan E; Flores I; Weidhaas JB; Taylor HS
    EMBO Mol Med; 2012 Mar; 4(3):206-17. PubMed ID: 22307873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of KRAS in Endometrial Cancer: A Mini-Review.
    Sideris M; Emin EI; Abdullah Z; Hanrahan J; Stefatou KM; Sevas V; Emin E; Hollingworth T; Odejinmi F; Papagrigoriadis S; Vimplis S; Willmott F
    Anticancer Res; 2019 Feb; 39(2):533-539. PubMed ID: 30711927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRP 1846C>T Genetic Polymorphism Is Associated with Lymph Node Metastasis and/or Severe Lymphatic Invasion in Endometrial Cancer.
    Kito M; Motoyama S; Fujita K; Miura M; Nanjo H; Sato N; Shimizu D; Sato T; Makino K; Sugawara T; Kato A; Tamura D; Takahashi K; Kumazawa Y; Sato W; Miura H; Shirasawa H; Sato A; Kumagai J; Terada Y
    Tohoku J Exp Med; 2015 Sep; 237(1):25-30. PubMed ID: 26310275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
    Lee LJ; Ratner E; Uduman M; Winter K; Boeke M; Greven KM; King S; Burke TW; Underhill K; Kim H; Boulware RJ; Yu H; Parkash V; Lu L; Gaffney D; Dicker AP; Weidhaas J
    PLoS One; 2014; 9(4):e94167. PubMed ID: 24732316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
    Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
    Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
    Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B
    J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.
    Marinović S; Škrtić A; Catela Ivković T; Poljak M; Kapitanović S
    Hum Cell; 2021 Sep; 34(5):1455-1465. PubMed ID: 34235620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
    Caiola E; Rulli E; Fruscio R; Buda A; Broggini M; Marabese M
    Am J Cancer Res; 2012; 2(3):298-308. PubMed ID: 22679560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.